Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Adaptive Bayesian analysis of serum creatinine as a marker for drug-induced renal impairment in an early-phase clinical trial.

Sottas PE, Kapke GF, Leroux JM.

Clin Chem. 2012 Nov;58(11):1592-6. doi: 10.1373/clinchem.2012.193698. Epub 2012 Sep 18.

2.

Adaptive Bayesian approach to clinical trial renal impairment biomarker signal from urea and creatinine.

Sottas PE, Kapke GF, Leroux JM.

Int J Biol Sci. 2013;9(2):156-63. doi: 10.7150/ijbs.5225. Epub 2013 Jan 26.

3.

Screening for renal disease using serum creatinine: who are we missing?

Duncan L, Heathcote J, Djurdjev O, Levin A.

Nephrol Dial Transplant. 2001 May;16(5):1042-6.

PMID:
11328914
4.

Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.

Rashid ST, Salman M, Agarwal S, Hamilton G.

Eur J Vasc Endovasc Surg. 2006 Sep;32(3):294-9. Epub 2006 May 23.

7.

Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.

Moist L, Sontrop JM, Gallo K, Mainra R, Cutler M, Freeman D, House AA.

Am J Kidney Dis. 2010 Oct;56(4):643-50. doi: 10.1053/j.ajkd.2010.03.028. Epub 2010 Jun 11.

PMID:
20541301
8.

Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.

Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS.

Circulation. 2004 Sep 21;110(12):1620-5. Epub 2004 Aug 30.

9.

A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia.

Jenik AG, Ceriani Cernadas JM, Gorenstein A, Ramirez JA, Vain N, Armadans M, Ferraris JR.

Pediatrics. 2000 Apr;105(4):E45.

PMID:
10742366
10.
11.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
12.

[Assessing renal function in elderly people].

Maftei ID, Cepoi V, Covic A.

Rev Med Chir Soc Med Nat Iasi. 2007 Jan-Mar;111(1):27-38. Review. Romanian.

PMID:
17595843
13.

Serum cystatin C in pregnant women: reference values, reliable and superior diagnostic accuracy.

Babay Z, Al-Wakeel J, Addar M, Mittwalli A, Tarif N, Hammad D, Ali N, Al-Askar A, Choudhary AR.

Clin Exp Obstet Gynecol. 2005;32(3):175-9.

PMID:
16433158
14.

Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.

Young A, Hodsman AB, Boudville N, Geddes C, Gill J, Goltzman D, Jassal SV, Klarenbach S, Knoll G, Muirhead N, Prasad GV, Treleaven D, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network.

Am J Kidney Dis. 2012 Jun;59(6):761-9. doi: 10.1053/j.ajkd.2011.09.019. Epub 2011 Nov 16.

PMID:
22093959
15.

Assessment of renal insufficiency in patients with normal serum creatinine levels undergoing angiography.

Mujtaba SH, Ashraf T, Mahmood SN, Anjum Q.

J Pak Med Assoc. 2010 Nov;60(11):915-7.

PMID:
21375194
16.

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J.

Am J Kidney Dis. 2007 Dec;50(6):946-51.

PMID:
18037095
17.

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.

Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.2165/11592950-000000000-00000.

PMID:
21967071
18.
19.

Subclinical changes in serum creatinine and mortality after coronary artery bypass grafting.

Tolpin DA, Collard CD, Lee VV, Virani SS, Allison PM, Elayda MA, Pan W.

J Thorac Cardiovasc Surg. 2012 Mar;143(3):682-688.e1. doi: 10.1016/j.jtcvs.2011.09.044. Epub 2011 Nov 4.

20.

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Levy A, Albiges-Sauvin L, Massard C, Izzedine H, Ederhy S, Bahleda R, Gomez-Roca C, Chargari C, Brocheriou-Spelle I, Soria JC.

Invest New Drugs. 2012 Jun;30(3):1116-20. doi: 10.1007/s10637-011-9671-z. Epub 2011 Apr 21. Erratum in: Invest New Drugs. 2012 Jun;30(3):1276. Edhery, Stéphane [corrected to Ederhy, Stéphane].

PMID:
21509469

Supplemental Content

Support Center